Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7186422 | 0.91 | L3MBTL1 (0.42) | CYP2D6CYP3A4SLC6A9ALDH1A1DRD2 | |
| SCHEMBL7830977 | 0.91 | SIGMAR1 (0.46) | SIGMAR1CYP2D6CYP3A4TMEM97ALDH1A1 | |
| SCHEMBL6168151 | 0.90 | SIGMAR1 (0.50) | SIGMAR1CYP2D6ALDH1A1TSHRCHRM2 | |
| SCHEMBL6598530 | 0.86 | OPRM1 (0.52) | SLC6A9DRD2DRD1DRD4DRD5 | |
| SCHEMBL6598136 | 0.83 | SIGMAR1 (0.51) | SIGMAR1CYP2D6CYP3A4TMEM97ALDH1A1 | |
| SCHEMBL6599122 | 0.83 | OPRD1 (0.60) | — | |
| SCHEMBL6599092 | 0.81 | LMNA (0.55) | SIGMAR1CYP2D6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL6599402 | 0.81 | SLC6A9 (0.48) | CYP2D6CYP3A4SLC6A9ALDH1A1CYP1A2 | |
| SCHEMBL4272060 | 0.81 | SIGMAR1 (0.60) | SIGMAR1CYP2D6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL6599265 | 0.78 | OPRD1 (0.59) | CYP2D6CYP3A4ALDH1A1CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140835-B1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PROD INC (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | PFIZER INC | 2004-04-01 | — | — | US | disclosed |
| US-6586431-B1 | Treating drug abuse and drug dependence; nervous system and gastrointestinal disorders | PFIZER INC | 2003-07-01 | — | — | US | disclosed |
| US-6503905-B1 | Treating nervous system and gastrointestinal disorders; analgesics, antiasthmatics | PFIZER INC | 2003-01-07 | — | — | US | disclosed |
| EP-1140835-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039091-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | BCHE, HTR3C, CHRM2 | SIGMAR1 221/4885CYP2D6 19/4885CYP3A4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.